Table 4 Clinicopathologic characteristics, adjuvant therapy, and survival outcomes of the deceased
Stage, grade, histology | Uterine size (weeks) | Adjuvant therapy | Site of recurrence | Progression free survival (months) | Overall survival (months) | Death status |
|---|---|---|---|---|---|---|
IA, 1 endometrioid | 14 | none | N/A | N/A | 51.2 | DICD (pulmonary disease) |
IA, 2 endometrioid | 14 | none | carcinomatosis | 16.1 | 18.3 | DOD |
IB carcinosarcoma | 12 | WPRT | RLQ mass | 8.3 | 10.7 | DOD |
IIIA serous | Not recorded | Carboplatin/ Taxol IMRT | carcinomatosis | 14.1 | 17.4 | DOD |
IIIC-1, 3 endometrioid | 13 | Carboplatin/ Taxol | Pulmonary, mediastinal | 18.0 | 30.6 | Unknown causea |
IIIC-2 serous | 15 | Carboplatin/ Taxol External beam pelvic radiation | N/A | N/A | 7.7 | DOD |
IVB carcinosarcoma | 10 | none | carcinomatosis | 1.6 | 2.8 | DOD |